Eli Lilly highlights key R&D catalysts for 2018; Vernalis and Daiichi Sankyo work together on cancer targets
→ Eli Lilly has a few key R&D catalysts built in to its 2018 forecast, out today. Holding the line on an R&D budget …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
